Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, PM14, PM534 and PM54. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.
Looking for a particular PharmaMar employee's phone or email?
PharmaMar Questions
The PharmaMar annual revenue was $171.4 million in 2026.
Javier Jimenez is the Chief Medical Officer of PharmaMar.
360 people are employed at PharmaMar.
PharmaMar is based in Colmenar Viejo, Madrid.
The NAICS codes for PharmaMar are [325, 32, 32541, 3254].
The SIC codes for PharmaMar are [28, 283].
Top PharmaMar Employees
-
Javier Jimenez
Chief Medical Officer at PharmaMar
Colmenar Viejo, ES13 -
11
-
21 -
2
-
21
-
23
Related Companies
